The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Open accessAbstract
The β-haemoglobinopathies, such as sickle cell disease and β-thalassaemia, are caused by mutations in the β-globin (HBB) gene and affect millions of people worldwide. Ex vivo gene correction in patient-derived haematopoietic stem cells followed by autologous transplantation could be used to cure β-haemoglobinopathies. Here we present a CRISPR/Cas9 gene-editing system that combines Cas9 ribonucleoproteins and adeno-associated viral vector delivery of a homologous donor to achieve homologous recombination at the HBB gene in haematopoietic stem cells. Notably, we devise an enrichment model to purify a population of haematopoietic stem and progenitor cells with more than 90% targeted integration. We also show efficient correction of the Glu6Val mutation responsible for sickle cell disease by using patient-derived stem and progenitor cells that, after differentiation into erythrocytes, express adult β-globin (HbA) messenger RNA, which confirms intact transcriptional regulation of edited HBB alleles. Collectively, these preclinical studies outline a CRISPR-based methodology for targeting haematopoietic stem cells by homologous recombination at the HBB locus to advance the development of next-generation therapies for β-haemoglobinopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, several reports have shown efficient Glu6Val correction in SCD-HSPCs, although correction efficiency can sometimes be linked with off-target INDELs in the same edited population15,16,45,46.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“RNP delivery results in an initially high level of the genome editing machinery followed by rapid decay, leading to a “fast on, fast off” strategy that results in highly efficient editing while minimizing OTEs13–19.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AAV6 homologous donor DNA templates are an efficient way to deliver donor templates for sensitive primary immune cells, including HSPCs and T-Cells15,35–40.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies have shown that disease-causing genetic errors can be corrected using CRISPR/Cas9 in long-term engrafting HSPCs that are preserved in downstream effector lineages15,16,24,25.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Major progress in delivering to 44 and handling HPSCs has resulted in formidable efficiencies of mutation correction or mitigation 18,45-47 that are expected to be curative.”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [45]
Experimental — accuracy not yet measured
In the citing paper
“Furthermore, CRISPR/Cas9 system holds tremendous promise for gene therapy [46–51]. It can correct causal mutations in the original genome and rescue the disease phenotypes of monogenic disorders permanently, which currently represents the most translatable field in CRISPR/Cas9-mediated disease therapy.”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Easy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Gene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-Leukemia
Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, M., Rossini, S., Mavilio, F., Traversari, C., et al. (1997) · Science · doi:10.1126/science.276.5319.1719 · Cited by 1,158
Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells
Hendel, A., Bak, R. O., Clark, J. T., Kennedy, A. B., Ryan, D. E., Roy, S., Steinfeld, I., Lunstad, B. D., Kaiser, R. J., Wilkens, A. B., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3290 · Cited by 1,090
Self-citationIsolation of a candidate human hematopoietic stem-cell population.
Baum, C. M., Weissman, I. L., Tsukamoto, A. S., Buckle, A., & Péault, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2804 · Cited by 1,084
Hematopoietic stem cell: self‐renewal versus differentiation
Seita, J., & Weissman, I. L. (2010) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.86 · Cited by 997
Cited by
Sorted by citations
Items 701–800 of 864
Aprile, A., Lidonnici, M. R., & Ferrari, G. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102419 · Cited by 2
Expanding the CRISPR/Cas toolkit: applications in proteomics and theranostics
Punde, A., Dey, S., Pandire, R., Bhattacharjee, A., & Patra, C. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1713700 · Cited by 2
Goswami, S. G., Gupta, P., Arvinden, V. R., Bhargava, N., Iyer, A. R., Saravanakumar, V., Yadav, P., Jha, S. K., Singh, S., Kumar, A., et al. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04582-1 · Cited by 2
Sumikawa, T., Ohno, S., Watanabe, T., Yamamoto, R., Yamano, M., Mori, T., Mori, K., Tobimatsu, T., & Sera, T. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00979 · Cited by 2
Gene therapy and editing in the treatment of hereditary blood disorders: Medical and ethical aspects
Alburquerque, P. C., Gómez‐Tatay, L., & Aznar, J. (2021) · Clinical Ethics · doi:10.1177/14777509211057255 · Cited by 2
Pediatric Bone Marrow Transplantation
Yadav, S. P., Sharma, A., Shah, R. M., & Satwani, P. (2021) · Organ and tissue transplantation · doi:10.1007/978-3-030-36358-1_11 · Cited by 2
Novel Nanotechnology-Based Vector Delivery in CRISPR System for Transgene-Free Editing
Saeed, S., Ahmed, A., Nizamuddin, S., Qureshi, S. S., Shahzad, R., Khan, N. U., Shaban, M., Khan, M. H. U., & Khan, S. U. (2022) · Springer eBooks · doi:10.1007/978-3-030-96925-7_12 · Cited by 2
Li, B., Li, Q., Qi, Z., Li, Z., Yan, X., Chen, Y., Xu, X., Pan, Q., Chen, Y., Huang, F., et al. (2024) · Angewandte Chemie · doi:10.1002/ange.202316323 · Cited by 2
Ingrungruanglert, P., Phodang, S., Amarinthnukrowh, P., Meehart, P., Pratedrat, P., Suratannon, N., Shotelersuk, V., Suphapeetiporn, K., & Israsena, N. (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2508-0983 · Cited by 2
Analysis of determinant factors of liver fibrosis progression in ex-thalassemic patients
Rostami, T., Monzavi, S. M., Poustchi, H., Khoshdel, A., Behfar, M., & Hamidieh, A. A. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02998-4 · Cited by 2
Behrmann, L., McComb, S., Aguadé-Gorgorió, J., Huang, Y., Hermann, M., Pelczar, P., Aguzzi, A., Bourquin, J., & Bornhauser, B. C. (2017) · BIO-PROTOCOL · doi:10.21769/bioprotoc.2222 · Cited by 2
Gene Editing in Regenerative Medicine
Fang, Y., Chen, X., & Godbey, W. T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809880-6.00042-4 · Cited by 2
Prenatal Treatment of Genetic Diseases in the Unborn
Verweij, E. J. T., & Oepkes, D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814189-2.00020-7 · Cited by 2
Advances in transplantation and gene therapy in transfusion-dependent β-thalassemia
Angelucci, E., & Abutalib, S. A. (2018) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.25 · Cited by 2
An introduction to CRISPR-Cas systems for reprogramming the genome of mammalian cells
Singh, V. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.010 · Cited by 2
The Fabulous Impact of CRISPR Method in Sickle Cell Disease Treatment
Ebrahimi, V., & Hashemi, A. (2021) · Trends in Peptide and Protein Sciences · doi:10.22037/tpps.v6i.34202 · Cited by 2
Stem Cell-Based Therapeutic Approaches in Genetic Diseases
Aslan, A., & Yuka, S. A. (2023) · Advances in experimental medicine and biology · doi:10.1007/5584_2023_761 · Cited by 2
Gene Therapy Challenges and Success
Jadhav, M. S. D., Rajguru, M. J. R., & Shirsat, M. H. U. M. |. D. M. K. (2020) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.3892732 · Cited by 2
Immunostimulatory guide RNAs mediate potent antiviral responsePreprint
Cai, Y., Knudsen, A., Windross, S. J., Thomsen, M. K., & Paludan, S. R. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/282558 · Cited by 2
The Global State of Genome EditingPreprint
Siwo, G. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/341198 · Cited by 2
TRACE-Seq Reveals Clonal Reconstitution Dynamics of Gene Targeted Human Hematopoietic Stem CellsPreprint
Sharma, R., Dever, D. P., Lee, C. M., Azizi, A., Pan, Y., Camarena, J., Köhnke, T., Bao, G., Porteus, M. H., & Majeti, R. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.25.115329 · Cited by 2
Self-citationHigh-Level Correction of the Sickle Mutation is Amplified in Vivo During Erythroid DifferentiationPreprint
Magis, W., DeWitt, M. A., Wyman, S. K., Vu, J. T., Heo, S., Shao, S. J., Hennig, F., Romero, Z. G., Fernandez, B. C., Said, S., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3985189 · Cited by 2
Osada, E., Manome, Y., & Sato, Y. (2025) · Data in Brief · doi:10.1016/j.dib.2025.111359 · Cited by 2
Rapid and Robust Generation of Homozygous Fluorescent Reporter Knock-In Cell Pools by CRISPR-Cas9
Yang, J., Guo, F., Chin, H. S., Chen, G. B., Zhang, Z., Williams, L., Kueh, A. J., Chow, P. K. H., Herold, M. J., & Fu, N. Y. (2025) · Cells · doi:10.3390/cells14151165 · Cited by 1
“This delivery method remains challenging to use for many cell types and often requires large amounts of DNA, which can compromise cell viability and lead to substantial random integration [6].”
Li, Z., Li, C., Xiao, S., & Liang, H. (2025) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00715 · Cited by 1
Liang, X., Li, Y., Xiao, S., Liu, H., Wang, J., Wang, Y., Yang, Y., & Gao, C. (2024) · Nano Research · doi:10.26599/nr.2025.94907516 · Cited by 1
Sharma, D., Sinha, R., Lesch, B. J., & Cromer, M. K. (2025) · STAR Protocols · doi:10.1016/j.xpro.2025.104018 · Cited by 1
Sweileh, M. W. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03957-0 · Cited by 1
Kosaka, Y., Lopez, B., Kishimoto, N. Y., Jacob, S. P., Montenont, E., Huallanca, R., Coughenour, G., Paola, J. D., Ross, J. E., Lee, K., et al. (2025) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2025.11.004 · Cited by 1
Engineered AcrIIA5 for optogenetic control of CRISPR‐Cas9‐based genome editing
Chen, Q., Yao, J., Lu, Y., Qiu, R., Deng, Z., & Sun, Y. (2025) · mLife · doi:10.1002/mlf2.70016 · Cited by 1
Complex HBB gene editing outcomes revealed by a fluorescent reporter cell model
Karsenty, C. L., Betancourth, D., Cao, M., Pham, Q.-K., Park, S. H., & Bao, G. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102854 · Cited by 1
CRISPR in Thalassemia: Global Research Trend Analysis
Saboor, M., Alblooshi, M. J., Alkaabi, A. A., Soozaei, F. R., & Alketbi, M. H. (2026) · Hemoglobin · doi:10.1080/03630269.2026.2634815 · Cited by 1
Human embryo editing: 10 years of breakthroughs and challenges
Zhou, Y., Xie, D., Ding, C., Wu, W., Cao, T., Liu, Q., Keefe, D. L., 周灿权, & Huang, J. (2026) · Protein & Cell · doi:10.1093/procel/pwag030 · Cited by 1
Naseem, A., Vetharoy, W., Whittaker, T. E., Zinghirino, F., Carusillo, A., Ghosh, R., Gómez‐Castañeda, E., Ali, H., Cipriani, C., Montini, E., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201816 · Cited by 2
The rising young scientist stars in China
Cheng, H. L. (2016) · Protein & Cell · doi:10.1007/s13238-016-0347-5 · Cited by 1
A chance to cut (the genome) is a chance to cure
Montbleau, K. E., & Sankaran, V. G. (2018) · Blood · doi:10.1182/blood-2018-03-839787 · Cited by 1
Deola, S., Guerrouahen, B. S., Sidahmed, H., Al-Mohannadi, A., Elnaggar, M., Elsadig, R., Abdelalim, E. M., Petrovski, G., Gadina, M., Thrasher, A. J., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1652-y · Cited by 1
Research progress on non-viral vectors of CRISPR/Cas9 system
Liu, Q., Zhang, Z., & Liu, Y. (2019) · Scientia Sinica Chimica · doi:10.1360/n032018-00233 · Cited by 1
Gene Editing in Hematopoietic Stem Cells
Liao, J., & Wu, Y. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-99-7471-9_11 · Cited by 2
Bazazzadegan, N., Hasanzad, M., & Abedini, S. S. (2024) · Springer eBooks · doi:10.1007/978-981-97-4974-4_9 · Cited by 1
Engineered cytokine-expressing MSCs support ex vivo culture of human HSPCs and AML cells
Foßelteder, J., Brauchart, T., Schlacher, A., Sconocchia, T., Özkaya, E., Auinger, L., Schlenke, P., Sill, H., Zebisch, A., & Reinisch, A. (2025) · Experimental Hematology · doi:10.1016/j.exphem.2025.104790 · Cited by 1
Self-citationFard, G. B., Ahmadi, M. H., Gholamin, M., & Bafghi, M. H. (2025) · Current Research in Translational Medicine · doi:10.1016/j.retram.2025.103531 · Cited by 3
A CRISPR View of Biological Mechanisms
Martinez, E., Sanchez, L., Vázquez, N., Marks, R., Cedillo, R., Respondek, C., Holguin, M., Holguin, Persans, M. W., & Keniry, M. E. (2016) · Discoveries · doi:10.15190/d.2016.16 · Cited by 1
李, 大., 刘, 明., 王, 立., & 张, 晓. (2017) · Scientia Sinica Vitae · doi:10.1360/n052017-00208 · Cited by 1
Hematopoietic stem cell gene therapy: progress and challenges
Zhang, X., Cheng, T., & Zhang, J. (2017) · Scientia Sinica Vitae · doi:10.1360/n052017-00268 · Cited by 1
Geny, S., Hosseini, E. S., Concordet, J., & Giovannangeli, C. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788015714-00400 · Cited by 1
CRISPR-Cas9 for therapy: the challenges and ways to overcome them
Acharya, S., Maiti, S., & Chakraborty, D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818140-9.00009-x · Cited by 2
Application of the Scientific Method in Stem Cell Research
Tehamy, A. G., AlMoslemany, M. A., Ahmed, T. A., & El‐Badri, N. (2020) · Learning materials in biosciences · doi:10.1007/978-3-030-55359-3_12 · Cited by 1
Genome editing in lysosomal disorders
Pimentel-Vera, L. N., Poletto, É., Gonzalez, E. A., Poswar, F. D. O., Giugliani, R., & Baldo, G. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.02.001 · Cited by 1
Kumkhaek, C., Uchida, N., Tisdale, J. F., & Rodgers, G. P. (2021) · British Journal of Haematology · doi:10.1111/bjh.17564 · Cited by 1
Self-citationEnhanced precision and efficiency
Bashir, S., & Kühn, R. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0159-9 · Cited by 1
Pediatric Bone Marrow Transplantation
Yadav, S. P., Sharma, A., Shah, R. M., & Satwani, P. (2020) · Organ and tissue transplantation · doi:10.1007/978-3-319-64938-2_11-1 · Cited by 1
Rai, R., Vetharoy, W., Naseem, A., Steinberg, Z., Thrasher, A. J., Santilli, G., & Cavazza, A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.11.475795 · Cited by 1
TESOGENASE, An Engineered Nuclease Editor for Enhanced Targeted Genome IntegrationPreprint
Nam, H., Xie, K., Majumdar, I., Yang, S., Starzyk, J., Lee, D., Shan, R., Li, J., & Wu, H. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.28.553855 · Cited by 1
Kanke, K. L., Rayner, R. E., Abel, E., Venugopalan, A., Suu, M., Stack, J. T., Nouri, R., Guo, G., Vetter, T. A., Cormet‐Boyaka, E., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.01.578476 · Cited by 1
Feist, W. N., Luna, S. E., Ben-Efraim, K., Interrante, M. V. F., Amorin, N. A., Johnston, N. M., Bruun, T. U. J., Ghanim, H. Y., Lesch, B. J., Dudek, A. M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.08.583956 · Cited by 1
Self-citationLetort, G., Duclert, A., Clerre, D. L., Chion-Sotinel, I., Salvatori, R., Dessez, E., Sevin, M., Rotondi, M. C., Ducani, C., Duchateau, P. N., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.19.638978 · Cited by 1
Gomez‐Ospina, N., Vera, L. P., Gastou, M., Colella, P., Basurto, J. A., Feng, A., Lin, Y., Zhao, X., & Sun, Y. (2025) · Research Square · doi:10.21203/rs.3.rs-7123212/v1 · Cited by 1
Cell-stereotyped DNA repair outcomes are widespread during genome editingPreprint
Schlapansky, M. F., Schröder, M., Santinha, A. J., Rothgangl, T., Ioannidi, E. I., Cullot, G., Lewków, B., Ortega, G. C., Ahmed, N., Mailänder, D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.23.684114 · Cited by 2
Highly efficient and scarless genome editing via essential-gene-coupled homology-directed repairPreprint
Yeo, J. H., Kim, H. H., Oh, S. H., & Lee, J. (2026) · Genome Research · doi:10.1101/gr.281194.125 · Cited by 1
From the bedside to the bench: new discoveries on blood cell fate and function
Trompouki, E., Figueroa, E. F., Lucas, D., & Bowman, T. V. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.11.007
Genomeditierung in der Zell- und Gentherapie
Pruszak, J., Müller, M., König, S., & Cathomen, T. (2017) · Transfusionsmedizin · doi:10.1055/s-0043-105031
Research progress of hereditary blood diseases
HuiYuan, L. I., & Yang, R. (2017) · Scientia Sinica Vitae · doi:10.1360/n052017-00271
Genome Editing During Development Using the CRISPR-Cas Technology
Arzate‐Mejía, R. G., Licona-Limón, P., & Targa, F. R. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7714-7_16
CRISPR‐Cas9 : A New Tool for Gene Therapy
Sharma, S., Maiti, S., & Chakraborty, D. (2017) · Wiley eBooks · doi:10.1002/9780470015902.a0026629
The Potential of CRISPR/Cas9 in Hematotherapy
Bak, R. O. (2019) · Stem Cells and Development · doi:10.1089/scd.2019.0079
Self-citationPresent and Future Strategies with Curative Intent for Hereditary Hemoglobinopathies
Oliveira, V. G., Saraiva, A. F., Costa, F., & de Sousa, A. B. (2019) · OBM Transplantation · doi:10.21926/obm.transplant.1903086
[Research advances in transplantation for thalassemia major].
Huang, C.-W., & Jiang, H. (2020) · PubMed Central · doi:10.7499/j.issn.1008-8830.2020.01.015
Future technologies for preimplantation genetic applications
Kubikova, N., & Wells, D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816561-4.00016-8
Roman‐Rodriguez, F. J., Ugalde, L., Alvarez, L. A., Díez, B., Risueño, C., Cortón, M., Bogliolo, M., Ayuso, C., Ramı́rez, M. J., Rodríguez, S., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3285807
Base Editors Flex Sights on Sickle-Cell Disease
Cereseto, A., Cradick, T. J., & Davies, K. (2021) · The CRISPR Journal · doi:10.1089/crispr.2021.29125.kda
CRISPR/Cas9 technologies to manipulate human induced pluripotent stem cells
Jang, H., Moon, J., Kim, N., & Yoon, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85766-6.00012-7
Pattabhi, S., Lotti, S. N., Berger, M. P., Singh, S., & Rawlings, D. J. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.30.450644
Chaudhary, A. (2021) · Journal of Proteomics & Bioinformatics
CRISPR-Click Enables Multi-Gene Editing with Modular Synthetic sgRNAsPreprint
Park, H., Osman, E. A., Cromwell, C. R., Laurent, C. S., Liu, Y., Kitova, E. N., Klassen, J. S., Hubbard, B. P., Macauley, M. S., & Gibbs, J. M. (2021) · doi:10.33774/chemrxiv-2021-7pdz9
Cromer, M. K., Barsan, V. V., Jaeger, E. B., Wang, M., Hampton, J. P., Chen, F., Kennedy, D., Khrebtukova, I., Granat, A., Truong, T., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.27.466166
Self-citationRós, F. A. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2021.tde-04102021-161614
Huang, P., Chen, S. H., Shiver, A. L., Culver, R. N., Huang, K. C., & Buie, C. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.14.476275
Pediatric Bone Marrow Transplantation
Yadav, S. P., Sharma, A., Shah, R. M., & Satwani, P. (2020) · Organ and tissue transplantation · doi:10.1007/978-3-319-64938-2_11-2
Genome‐Editing Applications in Stem Cell Engineering and Regenerative Medicine
Gupta, P., Jaitly, S., Thakur, P., Goswami, S. G., Bhargava, N., & Ramalingam, S. (2022) · Wiley eBooks · doi:10.1002/9781119671404.ch17
Suh, Y. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737144813.793579904
Gene therapy for primary immune deficiencies
Kohn, D. B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816768-7.00058-2
Prasad, K. M., Devaraju, N., George, A., Ravi, N. S., Mahalingam, G., Rajendiran, V., Panigrahi, L., Venkatesan, V., Lakhotiya, K., Moorthy, Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.01.494256
Yang, F., Pang, J., Liu, G., Yang, Y., Qin, S., Zhang, Y., Lai, Y., Liang, D., & Wu, Y. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.05.506576
Rao, J. V., Naik, R. R., Venkanna, S., & Kumar, N. (2022) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815050837122010008
Deng, H., Liu, Y., & Sun, S. (2022) · Wiley eBooks · doi:10.1002/9781119692799.ch12
Gene editing for stem cells by CRISPR-Cas9
Teh, S. W., David, H. M. O., Koh, A. E.-H., Kumar, S. S., & Mok, P. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823729-8.00009-9
Hematopoietic Stem Cell-Targeted Gene Therapy Using Lentiviral Vectors
Uchida, N. (2023) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.19.205
Self-citationApplication of CRISPR-Cas12a technology in zebrafish to simulate ß-globin gene (HBB) mutationsPreprint
Shafique, F., Ali, S., Balckburn, E., & Hassan, M. U. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.21.558926
Mechanisms of Pol II Recruitment to the Human Beta-Globin Locus Control Region Super-Enhancer
Johnson, B., Gibbons, M., Bushra, F., Fang, Y., & Bungert, J. (2023) · UF Journal of Undergraduate Research · doi:10.32473/ufjur.25.133391
Therapeutics and Diagnostics Discovery
Mochly‐Rosen, D., Grimes, K., Hannoush, R. N., Koch, B., Ehrenkaufer, G. M., Erlanson, D. A., Saiki, J., Wilson, J. L., Aldred, S. F., Garcia, A. A., et al. (2023) · Springer eBooks · doi:10.1007/978-3-031-34724-5_2
Pérez-Bermejo, J. A., Efagene, O., Matern, W. M., Holden, J. K., Kabir, S., Chew, G. M., Andreoletti, G., Catton, E., Ennis, C. L., Garcia, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.16.567426
Self-citationUnderstanding genetic heterogeneity in gene-edited hematopoietic stem cell products
Becker, H., & Yamazaki, S. (2023) · Experimental Hematology · doi:10.1016/j.exphem.2023.11.007 · Cited by 1
Conventional and Innovative Molecular Approaches Developed for Treating Hemoglobinopathies
Miliotou, Α. N., Georgiou‐Siafis, S. K., Vlachaki, E., Pappas, I. S., Vizirianakis, I. S., Tsiftsoglou, A. S., & Papadopoulou, L. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00025-1
AAV-Vektoren – die imposante Karriere eines Parvovirus
Jäschke, N. M., & Büning, H. (2023) · Springer eBooks · doi:10.1007/978-3-662-67908-1_4
Application of CRISPR-Cas in disease diagnosis and management
Yadav, S., & Gupta, R. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-91808-4.00001-8
Genome Editing Technologies and Application in Medicine: Discoveries, Challenges, and Prospects
Lohrasbi, R., & Amiri‐Yekta, A. (2023) · Cell and Tissue Journal · doi:10.61186/jct.14.3.241
Applied Stem Cell Research in Sickle Cell Disease
Kiumarsi, A., Rostami, T., & Mohammadi, M. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00027-5
Metadata
- Authors
- Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., Uchida, N., Hendel, A., Narla, A., Majeti, R., Weinberg, K. I., & Porteus, M. H.
- Affiliations
- Stanford University (US)
- Institute for Stem Cell Biology and Regenerative Medicine (US)
- Stanford Medicine (US)
- Corresponding author
- Porteus, Matthew H.
- ORCID
- Venue
- Nature
- Published
- 2016-11-07
- Volume
- 539
- Issue
- 7629
- Pages
- 384-389
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5898607
- OpenAlex
- W2547418311
- Semantic Scholar
- 91eb4c33902b14df9b2974a4ce8dc6e3c3a02125
- Cited by
- 864
- References
- 50
- Citations by year
- 2026: 45 · 2025: 75 · 2024: 80 · 2023: 93 · 2022: 76 · 2021: 120 · 2020: 93 · 2019: 90 · 2018: 99 · 2017: 89 · 2016: 4
- FWCI
- 48.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (5r01ai120766-02, R01-AI120766)
- National Eye Institute (PN2EY018244)
- National Institute of General Medical Sciences (T32GM007266)
- National Institute of Allergy and Infectious Diseases (R01-AI120766, R01AI097320)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Keywords
- CRISPR/Cas9 genome editing, beta-globin gene, hematopoietic stem cells, sickle cell disease, beta-thalassemia, homologous recombination, adeno-associated virus vectors, Cas9 ribonucleoprotein, autologous transplantation, reporter genes
- MeSH terms
- Gene Editing, Dependovirus, Alleles, Anemia, Sickle Cell, Animals, Cell Differentiation, Cell Separation, Erythrocytes, Female, Flow Cytometry, Hematopoietic Stem Cells, Humans, Microspheres, Mutation, RNA, Messenger, Genetic Therapy, Mice, SCID, Mice, Inbred NOD, beta-Thalassemia, Genes, Reporter, Gene Targeting, Antigens, CD34, Cell Lineage, beta-Globins, Magnets, Homologous Recombination, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
